Harrow, Inc. (NASDAQ:HROW – Get Free Report) hit a new 52-week high on Thursday . The company traded as high as $47.55 and last traded at $47.30, with a volume of 76879 shares changing hands. The stock had previously closed at $45.33.
Analyst Ratings Changes
HROW has been the topic of a number of analyst reports. Lake Street Capital boosted their price target on Harrow from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, June 3rd. B. Riley reissued a “buy” rating and issued a $50.00 target price on shares of Harrow in a research note on Thursday, August 29th. Finally, Craig Hallum lifted their price target on Harrow from $30.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, August 9th.
Check Out Our Latest Stock Analysis on Harrow
Harrow Stock Performance
Harrow (NASDAQ:HROW – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.12. The firm had revenue of $48.94 million during the quarter, compared to analysts’ expectations of $42.78 million. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. Equities research analysts predict that Harrow, Inc. will post -0.38 earnings per share for the current year.
Institutional Trading of Harrow
Several institutional investors have recently made changes to their positions in HROW. nVerses Capital LLC purchased a new position in shares of Harrow in the second quarter worth $33,000. Allspring Global Investments Holdings LLC lifted its stake in Harrow by 2,730.7% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after purchasing an additional 2,048 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Harrow by 66.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,745 shares of the company’s stock worth $89,000 after buying an additional 2,682 shares during the period. Bayesian Capital Management LP bought a new position in shares of Harrow in the first quarter worth about $185,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Harrow by 6.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock worth $221,000 after acquiring an additional 1,033 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.
About Harrow
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Read More
- Five stocks we like better than Harrow
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- What is a Death Cross in Stocks?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Best Stocks Under $5.00
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.